Gas Therapies Including Hydrogen Show Promise for Brain Protection After Heart Attack
- Authors
- Giulia Merigo, Giuseppe Ristagno
- Journal
- Critical Care Clinics
- Year
- 2025
- DOI
- 10.1016/j.ccc.2025.08.004
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- Italy
- Health Condition
- Cardiac Arrest
- Body System
- Cardiovascular
TL;DR
Scientists found that special gases like hydrogen and xenon might protect people's brains after their heart stops, which could help them recover better and avoid permanent brain damage—but they need to do bigger tests first to make sure it actually works.
Key Finding
Molecular hydrogen and other therapeutic gases show promise for protecting brain function after cardiac arrest through antioxidant and anti-inflammatory mechanisms, but large-scale human trials are needed to confirm their effectiveness.
Summary
This review examines several gases—including molecular hydrogen, nitric oxide, xenon, and argon—that show promise for protecting the brain after cardiac arrest (when the heart stops beating). These gases appear to work by reducing harmful inflammation and cell damage in the brain. However, the authors note that while early research is encouraging, large clinical trials in humans are still needed to prove these treatments actually work and to figure out the best ways to use them.
Practical Takeaway
While this review suggests molecular hydrogen may have neuroprotective potential in cardiac arrest settings, it is a summary of early-stage research rather than a completed study. The authors explicitly state that large clinical trials have not yet been conducted, so there is no established evidence that hydrogen water or hydrogen gas therapies are effective for this or any other condition in humans at this time.
Abstract
Cardiac arrest (CA) remains a major cause of mortality and neurologic impairment, underscoring the urgent need for innovative neuroprotective strategies. Gas therapies, including inhaled nitric oxide (NO), molecular hydrogen (H2), xenon (Xe), and argon (Ar), have emerged as promising neuroprotective agents. These gases exert protective effects, preserving neurologic function and improving outcomes after CA through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. Despite promising preclinical and early clinical data, large-scale trials are essential to validate their efficacy, optimize protocols, refine dosing, and ensure clinical translation. Advancing gas therapies into standard post-CA care could revolutionize neuroprotection, offering a paradigm shift in resuscitation medicine.